Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spastic Paraplegia and Cognitive Impairment Due to a De Novo Pathogenic Variant in Presenilin-1.
Muñoz E, Jodar M, Guerrero J, Compta Y, Perissinotti A, Álvarez-Mora MI, Falgàs N, Rodríguez-Revenga L, Sánchez-Valle R. Muñoz E, et al. Among authors: perissinotti a. Mov Disord Clin Pract. 2022 Oct 23;10(1):148-150. doi: 10.1002/mdc3.13588. eCollection 2023 Jan. Mov Disord Clin Pract. 2022. PMID: 36699002 Free PMC article. No abstract available.
Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
Grau-Rivera O, Navalpotro-Gomez I, Sánchez-Benavides G, Suárez-Calvet M, Milà-Alomà M, Arenaza-Urquijo EM, Salvadó G, Sala-Vila A, Shekari M, González-de-Echávarri JM, Minguillón C, Niñerola-Baizán A, Perissinotti A, Simon M, Kollmorgen G, Zetterberg H, Blennow K, Gispert JD, Molinuevo JL; ALFA Study. Grau-Rivera O, et al. Among authors: perissinotti a. Alzheimers Res Ther. 2021 Feb 17;13(1):46. doi: 10.1186/s13195-021-00781-z. Alzheimers Res Ther. 2021. PMID: 33597012 Free PMC article.
Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers.
Salvadó G, Shekari M, Falcon C, Operto G, Milà-Alomà M, Sánchez-Benavides G, Cacciaglia R, Arenaza-Urquijo E, Niñerola-Baizán A, Perissinotti A, Minguillon C, Fauria K, Kollmorgen G, Suridjan I, Molinuevo JL, Zetterberg H, Blennow K, Suárez-Calvet M, Gispert JD; ALFA Study. Salvadó G, et al. Among authors: perissinotti a. Brain Commun. 2022 May 24;4(3):fcac134. doi: 10.1093/braincomms/fcac134. eCollection 2022. Brain Commun. 2022. PMID: 35702732 Free PMC article.
Melanoma & nuclear medicine: new insights & advances.
Perissinotti A, Rietbergen DD, Vidal-Sicart S, Riera AA, Olmos RAV. Perissinotti A, et al. Melanoma Manag. 2018 Jun 28;5(1):MMT06. doi: 10.2217/mmt-2017-0022. eCollection 2018 Jun. Melanoma Manag. 2018. PMID: 30190932 Free PMC article. Review.
Melanoma and nuclear medicine.
Perissinotti A, Vidal-Sicart S, Nieweg O, Valdés Olmos R. Perissinotti A, et al. Melanoma Manag. 2014 Aug;1(1):57-74. doi: 10.2217/mmt.14.10. Epub 2014 Sep 5. Melanoma Manag. 2014. PMID: 30190811 Free PMC article. Review.
Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4.
Sánchez-Benavides G, Salvadó G, Arenaza-Urquijo EM, Grau-Rivera O, Suárez-Calvet M, Milà-Alomà M, González-de-Echávarri JM, Minguillon C, Crous-Bou M, Niñerola-Baizán A, Perissinotti A, Gispert JD, Molinuevo JL; ALFA Study. Sánchez-Benavides G, et al. Among authors: perissinotti a. Alzheimers Dement (Amst). 2020 Nov 11;12(1):e12127. doi: 10.1002/dad2.12127. eCollection 2020. Alzheimers Dement (Amst). 2020. PMID: 33204815 Free PMC article.
Multitracer model for staging cortical amyloid deposition using PET imaging.
Collij LE, Heeman F, Salvadó G, Ingala S, Altomare D, de Wilde A, Konijnenberg E, van Buchem M, Yaqub M, Markiewicz P, Golla SSV, Wottschel V, Wink AM, Visser PJ, Teunissen CE, Lammertsma AA, Scheltens P, van der Flier WM, Boellaard R, van Berckel BNM, Molinuevo JL, Gispert JD, Schmidt ME, Barkhof F, Lopes Alves I; ALFA Study, for the Alzheimer's Disease Neuroimaging Initiative; AMYPAD Consortium. Collij LE, et al. Neurology. 2020 Sep 15;95(11):e1538-e1553. doi: 10.1212/WNL.0000000000010256. Epub 2020 Jul 16. Neurology. 2020. PMID: 32675080 Free PMC article.
Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile.
Milà-Alomà M, Shekari M, Salvadó G, Gispert JD, Arenaza-Urquijo EM, Operto G, Falcon C, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, Sánchez-Benavides G, González-de-Echávarri JM, Minguillon C, Fauria K, Niñerola-Baizán A, Perissinotti A, Simon M, Kollmorgen G, Zetterberg H, Blennow K, Suárez-Calvet M, Molinuevo JL; ALFA study. Milà-Alomà M, et al. Among authors: perissinotti a. Alzheimers Res Ther. 2021 Jul 27;13(1):134. doi: 10.1186/s13195-021-00863-y. Alzheimers Res Ther. 2021. PMID: 34315519 Free PMC article. Clinical Trial.
Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment.
Falgàs N, Tort-Merino A, Balasa M, Borrego-Écija S, Castellví M, Olives J, Bosch B, Férnandez-Villullas G, Antonell A, Augé JM, Lomeña F, Perissinotti A, Bargalló N, Sánchez-Valle R, Lladó A. Falgàs N, et al. Among authors: perissinotti a. Eur J Neurol. 2019 Aug;26(8):1098-1104. doi: 10.1111/ene.13945. Epub 2019 Mar 28. Eur J Neurol. 2019. PMID: 30793432
146 results